Ordering
Ordering ZERBAXA
Learn about:
- Wholesaler information
- Coding and billing
- Information regarding New Technology Add-on Payment (NTAP)
- References
Wholesaler information
Product: ZERBAXAPackaging: Carton contains 10 single-dose vials
National Drug Code (NDC): 67919-030-01Distributor order codes
Distributor | Order code for ZERBAXA |
---|---|
AMERISOURCEBERGEN DRUG CORP. | 10237721 |
BESSE MEDICAL | 10237721 |
CARDINAL HEALTH | 5045810 |
DMS PHARMACEUTICAL GROUP INC | 583420 |
FFF ENTERPRISES | ZER003001 |
MCKESSON CORPORATION | 3971686 |
METRO MEDICAL SUPPLY | 661074 |
MORRIS & DICKSON CO | 031179 |
SMITH DRUG COMPANY | 737924 |
Merck does not recommend the use of one authorized distributor over another. Merck does not make any warranty as to the services offered by any particular distributor.
Package size and dimensions

Not actual size.
Sales package size (carton):
10 single-dose 13.2 oz. vials
Carton dimensions:
6 5/16 x 2 11/16 x 2 9/16 inches
Coding and billing information
This resource contains a list of possible codes that may be relevant when billing for ZERBAXA® (ceftolozane and tazobactam). Please consult with the applicable payer or, where applicable, the Medicare Administrative Contractor, to understand the payer’s specific billing requirements.
You are solely responsible for determining the appropriate codes and for any action you take in billing. Information about HCPCS codes is based on guidance issued by the Centers for Medicare & Medicaid Services (CMS) applicable to Medicare and may not apply to other public or private payers. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness for a particular code and for information on additional codes.
The information available here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. This information is subject to change. Payer coding requirements may vary or change over time, so it is important to regularly check with each payer as to payer-specific requirements. The information available here is not intended to be conclusive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Merck and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.
HCPCS code for ZERBAXA1
HCPCS code | J0695 |
Description | Injection, ceftolozane 50 mg and tazobactam 25 mg |
Billing units | Each billing unit of ZERBAXA equals 50 mg of ceftolozane and 25 mg of tazobactam |
HCPCS, Healthcare Common Procedure Coding System; APC, ambulatory payment classifications.
Note: Paid under Outpatient Prospective Payment System (OPPS) as a separate APC payment.2
Use form CMS-1500 for in-office injection; in the hospital outpatient department setting, submit claims using form UB-04 (also known as CMS 1450).
For questions on billing if a portion of the package is wasted, consult the applicable payer’s policy regarding wastage. Please note that effective January 1, 2017, providers are required to use the JW modifier for Medicare claims with unused drugs or biologicals from single-use vials or single-use packages that are appropriately discarded.3
Drug administration current procedural terminology (CPT®) code4
CPT code | 96365 |
Description | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
CPT copyright © 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
Possible revenue codes for use in the hospital inpatient and hospital outpatient settings5
Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes.
Revenue code | Description |
---|---|
0636 | Drugs requiring detailed coding |
0250 | General pharmacy |
Administration codes for new technology add-on payment (NTAP)
Beginning October 1, 2021, Medicare will provide an NTAP for ZERBAXA® (ceftolozane and tazobactam) of up to $1,836.98 per qualifying case to inpatient prospective payment system (IPPS)–participating acute care hospitals, in cases where ZERBAXA is used to treat HABP/VABP. This NTAP payment will be incremental to the MS-DRG reimbursement for qualifying Medicare inpatient cases.6
Hospitals report use of ZERBAXA by recording an ICD-10-PCS code on the claim for the traditional Medicare admission, indicating that ZERBAXA was administered during the admission. These codes are recorded in the same section of the claim as other ICD-10-PCS codes applicable to the admission.6
The ICD-10-PCS codes that describe the administration of ZERBAXA, available for use on October 1, 2021, are6,7:
ICD-10-PCS code | Descriptor |
---|---|
XW03396 | Introduction of ceftozolane and tazobactam into peripheral vein, percutaneous approach, new technology group 6 |
XW04396 | Introduction of ceftozolane and tazobactam into central vein, percutaneous approach, new technology group 6 |
MS-DRG, Medicare severity diagnosis-related group; ICD-10-PCS, International Classification of Diseases, 10th Revision, Procedure Coding System.
You are solely responsible for determining the appropriate codes and for any action you take in billing. Merck and its agents make no warranties, express or implied, concerning the accuracy or appropriateness of this information for your particular use. The use of this information does not guarantee payment or that any payment received will cover your costs.